These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1489186)

  • 1. Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo.
    Mattie H; Sekh BA; van Ogtrop ML; van Strijen E
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2439-43. PubMed ID: 1489186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo.
    van Ogtrop ML; Mattie H; Guiot HF; van Strijen E; Hazekamp-van Dokkum AM; van Furth R
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1932-7. PubMed ID: 2291658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.
    Mattie H; van Dokkum AM; Brus-Weijer L; Krul AM; van Strijen E
    J Infect Dis; 1990 Sep; 162(3):717-22. PubMed ID: 2143771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
    Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
    J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
    Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model.
    Pechère JC; Vladoianu IR
    J Antimicrob Chemother; 1992 May; 29(5):563-73. PubMed ID: 1624394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals.
    Zemelman C; Bello H; Domínguez M; González G; Mella S; Zemelman R
    Diagn Microbiol Infect Dis; 2001; 40(1-2):41-3. PubMed ID: 11448562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB
    Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection.
    Peetermans WE; Hoogeterp JJ; Hazekamp-van Dokkum AM; van den Broek P; Mattie H
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1869-74. PubMed ID: 2149812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ex-vivo serum bactericidal activity of cefepime, ceftazidime and cloxacillin against Staphylococcus aureus.
    Dan M; Asherov J; Poch F
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):39-42. PubMed ID: 9990474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
    Jang W; Park YJ; Park KG; Yu J
    J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.
    Mimoz O; Jacolot A; Leotard S; Hidri N; Samii K; Nordmann P; Petitjean O
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3304-8. PubMed ID: 9835534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo activities of DQ-2556 and its mode of action.
    Tanaka M; Otsuki M; Nishino T
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2595-601. PubMed ID: 1482128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.
    Kalman D; Barriere SL; Johnson BL
    Antimicrob Agents Chemother; 1992 Feb; 36(2):453-7. PubMed ID: 1605609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.
    Mimoz O; Leotard S; Jacolot A; Padoin C; Louchahi K; Petitjean O; Nordmann P
    Antimicrob Agents Chemother; 2000 Apr; 44(4):885-90. PubMed ID: 10722486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal effect of combinations of antibiotic and antineoplastic agents against Staphylococcus aureus and Escherichia coli.
    Nyhlén A; Ljungberg B; Nilsson-Ehle I; Odenholt I
    Chemotherapy; 2002 May; 48(2):71-7. PubMed ID: 12011538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.